#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Philadelphia positive acute lymphocytic leukaemia Acute myeloid leukaemia Anal cancer Prostate cancer Non-Hodgkin's lymphoma Hairy cell leukaemia recurrent Adult T-cell lymphoma/leukaemia refractory Follicular lymphoma stage I Inflammatory myofibroblastic tumour Oesophageal atresia Immunodeficiency congenital Antisynthetase syndrome Neuropathy peripheral Cerebral arteriovenous malformation haemorrhagic Plasma cell myeloma refractory More trials…

    Learn about Rare Diseases

    Synovial sarcoma – Treatment Indolent systemic mastocytosis Pulmonary sarcoidosis – Treatment Erdheim-Chester disease – Diagnostics Lysosomal storage disorder – Treatment Glycogen storage disease type II – Life with Disease Alport’s syndrome – Trials in Disease Advanced systemic mastocytosis Angiosarcoma non-metastatic – Diagnostics Crigler-Najjar syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Allo-501A Collagenase Exl01 MOLNUPIRAVIR Mepolizumab Procarbazine Hydrochloride Guanabenz Acetate Eplontersen Ethanol, Anhydrous Stx-241 Tramazoline Hydrochloride Omp66 Vosilasarm Alendronic Acid Goserelin Eftilagimod Alfa Peppermint Oil L-Histidine Hydrochloride Reparixin Omp12 More therapies…

    Learn about Your Condition

    Abdominal infection Substance use disorder Epithelioid sarcoma Exfoliation glaucoma Primary hyperoxaluria Desmoid tumour Magnetic resonance imaging Richter's syndrome Angina pectoris Neuroblastoma recurrent End stage renal disease Macular telangiectasia Oesophageal disorder Appendicitis Glaucoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Zanidatamab, tucatinib, capecitabine or eribulin mesylate in HER2-positive advanced breast cancer in adults

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    • Breast cancer
    Investigated Drugs:
    • Loperamide Hydrochloride
    • Tucatinib
    • Eribulin Mesylate
    Spain

  • A study to evaluate the safety of OMN6 in patients with pneumonia caused by Acinetobacter baumannii bacteria.

    Recruiting

    2 1 1
    Investigated Diseases:
    • Pneumonia bacterial
    Investigated Drugs:
    • Saline
    Greece Hungary Italy

  • A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Rilvegostomig
    • Ramucirumab
    • Infliximab
    France Italy Spain

  • Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Volrustomig
    • Cisplatin
    • Fluorouracil
    Germany Italy

  • Modafinil for Severe Fatigue in Patients with Quiescent Inflammatory Bowel Disease

    Recruiting

    4 1 1
    Investigated Diseases:
    • Chronic fatigue syndrome
    Investigated Drugs:
    • Modafinil
    • Placebo
    The Netherlands

  • Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect

    Recruiting

    3 1 1
    Investigated Drugs:
    • Cenegermin
    • Oxybuprocaine Hydrochloride
    • Tetracaine Hydrochloride
    Czechia France Germany Hungary Italy The Netherlands +2
Previous Page
1 … 18 19 20 21 22 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!